Friday 16 October 2026
Export EVMN’s income statement to Excel — free account
Evommune Inc.
EVMN Healthcare Biotechnology
Evommune Inc.’s revenue for fiscal 2025 (year ended December 2025) was $13.0 million, up 85.7% from fiscal 2024. In the quarter to June 2026, EPS grew 89.9% and free cash flow grew 21.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
5.17
0.76
−12.82%
Follow EVMN
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | — | — | — | 13.89 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | — | — | — | — | 24.03 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | — | — | 45 | 48 | ||||
| Revenue/emp, $m | — | — | — | — | — | — | — | — | 0.16 | 0.27 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | 7 | 13 | ||||
| Gross margin, % | — | — | — | — | — | — | — | — | 100.00 | 100.00 | |||||
| EBT | — | — | — | — | — | — | — | — | (67) | (69) | |||||
| EBT margin, % | — | — | — | — | — | — | — | — | (954.40) | (529.77) | |||||
| Net income | — | — | — | — | — | — | — | — | (67) | (69) | |||||
| Depreciation | — | — | — | — | — | — | — | — | 1 | 1 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | — | 4.64 | 2.12 | ||||
| Earnings | — | — | — | — | — | — | — | — | (45.29) | (11.22) | |||||
| Cash flow | — | — | — | — | — | — | — | — | (38.59) | (12.46) | |||||
| Capex | — | — | — | — | — | — | — | — | (0.06) | (0.04) | |||||
| Free cash flow | — | — | — | — | — | — | — | — | (38.65) | (12.49) | |||||
| Book value | — | — | — | — | — | — | — | — | 31.52 | 33.50 | |||||
| Shares, m | — | — | — | — | — | — | — | — | 2 | 6 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | 0.00 | 0.00 | ||||
| P/S | — | — | — | — | — | — | — | — | 0.00 | 0.00 | |||||
| P/B | — | — | — | — | — | — | — | — | 0.00 | 0.51 | |||||
| EV/Sales | — | — | — | — | — | — | — | — | 0.00 | 0.00 | |||||
| EV/FCF | — | — | — | — | — | — | — | — | 0.57 | 0.57 | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | — | (58) | (76) | ||||
| Capex | — | — | — | — | — | — | — | — | 0 | 0 | |||||
| Free cash flow | — | — | — | — | — | — | — | — | (58) | (77) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | — | 46 | 136 | ||||
| Total debt | — | — | — | — | — | — | — | — | 1 | 0 | |||||
| Net debt | — | — | — | — | — | — | — | — | (72) | (149) | |||||
| Shareholders’ equity | — | — | — | — | — | — | — | — | 48 | 206 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | — | 0.00 | (45.76) | ||||
| ROIC | — | — | — | — | — | — | — | — | 0.00 | (89.61) | |||||
| ROE | — | — | — | — | — | — | — | — | 0.00 | (224.59) | |||||
Negative figures in brackets.
Fiscal years to Dec 2025 · latest quarter Sep 2025
Charts ten years each
Evommune Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| KROS Keros Therapeutics, Inc. | $220.1M | — (loss-making) | — (loss-making) | −99.83% (below 0%: shrinking) | n/m | +32.19% (above 0%: growing) | 100.00% | 0.00% | Compare |
| PLX Protalix BioTherapeutics, Inc. | $217.5M | 10.9× | 10.2× | +27.07% (above 0%: growing) | +2,280.95% (above 0%: growing) | −94.09% (below 0%: shrinking) | 60.99% | 23.48% | Compare |
| CAMP CAMP4 Therapeutics Corporation | $216.5M | — (loss-making) | — (loss-making) | +18.84% (above 0%: growing) | n/m | −23.90% (below 0%: shrinking) | 100.00% | (752.11%) | Compare |
| PYXS Pyxis Oncology, Inc. | $215.3M | — (loss-making) | — (loss-making) | — | n/m | −5.46% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| EVMN Evommune Inc. | $215.2M | — (loss-making) | — (loss-making) | — | n/m | +21.78% (above 0%: growing) | 100.00% | 0.00% | |
| MGNX MacroGenics, Inc. | $214.7M | — (loss-making) | — (loss-making) | +377.97% (above 0%: growing) | n/m | +12.88% (above 0%: growing) | 100.00% | (42.19%) | Compare |
| ALEC Alector, Inc. | $213.3M | — (loss-making) | — (loss-making) | −57.84% (below 0%: shrinking) | n/m | +30.19% (above 0%: growing) | 100.00% | (734.73%) | Compare |
| IFRX InflaRx N.V. | $212.2M | — (loss-making) | — (loss-making) | −128.93% (below 0%: shrinking) | n/m | +69.33% (above 0%: growing) | 14,029.95% | 0.00% | Compare |
| ZNTL Zentalis Pharmaceuticals, Inc. | $212.1M | — (loss-making) | — (loss-making) | — | n/m | −9.06% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| Median of peers | $215.0M | — | — | −19.50% | — | +3.71% | 100.00% | 0.00% |
Evommune Inc. (EVMN) key facts
- Strength: Evommune Inc.’s revenue for fiscal 2025 (year ended December 2025) was $13.0 million, up 85.7% from fiscal 2024.
- Evommune Inc. (EVMN) is a Biotechnology company in the Healthcare sector, listed on the New York Stock Exchange.
- As of October 16, 2026, EVMN traded at $5.17, a market capitalization of $215.2 million.
- Return on equity was −224.6% and debt-to-equity 0.00.
- Its Altman Z-score is 1.47 (distress zone) for fiscal 2025.